<DOC>
	<DOCNO>NCT00610506</DOCNO>
	<brief_summary>Aims Study : The aim study 1 ) examine clinical utility escitalopram patient major depression atypical feature ; 2 ) evaluate tolerability escitalopram major depression atypical feature . Study hypothesis objective . This study propose open-label study gather pilot data examine whether escitalopram clinical utility treatment major depression atypical feature . Because exploratory nature design , specific study hypothesis generate regard efficacy drug . Our primary hypothesis effect size escitalopram atypical depression similar effect size escitalopram major depression , FDA approve indication .</brief_summary>
	<brief_title>Escitalopram ( Lexapro® ) In Patients With Major Depression With Atypical Features</brief_title>
	<detailed_description>Based treatment outcome , longitudinal course , biologic physiologic data , family history ( Rabkin et al. , 1996 ) , American Psychiatric Association 's Diagnostic Statistical Manual , Fourth Edition ( DSM-IV ) ( American Psychiatric Association , 1994 ) add atypical feature parenthetical modifier major depression dysthymia . Several recent report suggest DSM-IV criterion depression atypical feature identify group distinguishable cluster symptom , age onset course illness . The symptom constellation consist depressed mood , along hyperphagia , weight gain , increase fatigue rejection sensitivity . Some author distinguish two subtypes atypical depression . One subtype early onset ( i.e. , age 20 year ) chronic course ( i.e. , spontaneous well-being since onset great 2 month ) ( early/chronic atypical ) likely benefit tricyclic antidepressant placebo ( Stewart et al. , 2002 ) , respond monoamine oxidase inhibitor , increase leave hemisphere perceptual processing ( Stewart et al. , 2003 ) . In contrast , subtype report either later onset less chronic course illness ( late/nonchronic atypical ) respond robustly tricyclic antidepressant ( Stewart et al. , 2002 ) , show evidence increase leave hemispheric processing ( Stewart et al. , 2003 ) . The role new medication treatment depress patient atypical feature remain elucidated . One study compare outcome phenelzine fluoxetine , report difference , risk type II error large ( Pande et al . 1996 ) . A second study limit depressed patient atypical feature compare fluoxetine , imipramine , placebo , find drug effective half patient superior placebo , different ( McGrath et al . 2000 ) . A 12-week study compare moclobemide sertraline treatment outpatient atypical depression find drug produce comparable improvement ( Sogaard et al , 1999 ) . Falkai ( 1999 ) assert efficacy mirtazapine depression atypical feature without data , Rye et al . ( 1998 ) report single case apparently late onset atypical depression respond bupropion . A placebo control study fail show benefit mianserin atypical depression ( McGrath et al , 1985 ) . Finally , unmarketed drug , gepirone , demonstrate effective depression atypical feature comparison make antidepressant medication ( McGrath et al. , 1994 ) . Escitalopram approve treatment major depression Generalized Anxiety Disorder . However whether escitalopram improve atypical depressive symptom investigate . Aims Study : The aim study 1 ) examine clinical utility escitalopram patient major depression atypical feature ; 2 ) evaluate tolerability escitalopram major depression atypical feature . Study hypothesis objective . This study propose open-label study gather pilot data examine whether escitalopram clinical utility treatment major depression atypical feature . Because exploratory nature design , specific study hypothesis generate regard efficacy drug . Our primary hypothesis effect size escitalopram atypical depression similar effect size escitalopram major depression , FDA approve indication .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>1. age 18 65 year , 2 . DSMIV episode Major Depression nonpsychotic atypical feature . 3 . ≥19 score 29item HAMD , 4. ability give inform consent , patient childbearing potential 5 . A minimum 2week washout exist psychotropics ( 5 week fluoxetine ) . 1. bipolar depression , 2 . Any Axis I psychotic disorder 3. currently suicidal suicide risk , 4. history substance abuse previous 12 month , 5. history hypersensitivity escitalopram , citalopram 6. serious unstable medical disorder , 7. start terminate psychotherapy previous 12 week , 8 . ECT treatment previous 3 month , 9. pregnancy planning pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Atypical Depression</keyword>
</DOC>